SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 05, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 05, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines